- Home
- KLRS vs MYO Comparison
KLRS vs MYO Comparison
Compare KLRS & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- MYO
- Stock Information
- Founded
- KLRS 2019
- MYO 2004
- Country
- KLRS United States
- MYO United States
- Employees
- KLRS N/A
- MYO N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- MYO Industrial Specialties
- Sector
- KLRS Health Care
- MYO Health Care
- Exchange
- KLRS Nasdaq
- MYO Nasdaq
- Market Cap
- KLRS 129.0M
- MYO 153.0M
- IPO Year
- KLRS N/A
- MYO 2017
- Fundamental
- Price
- KLRS $2.40
- MYO $2.44
- Analyst Decision
- KLRS Buy
- MYO Strong Buy
- Analyst Count
- KLRS 1
- MYO 4
- Target Price
- KLRS N/A
- MYO $9.63
- AVG Volume (30 Days)
- KLRS 46.4K
- MYO 531.3K
- Earning Date
- KLRS 08-15-2025
- MYO 08-05-2025
- Dividend Yield
- KLRS N/A
- MYO N/A
- EPS Growth
- KLRS N/A
- MYO N/A
- EPS
- KLRS N/A
- MYO N/A
- Revenue
- KLRS N/A
- MYO $38,628,624.00
- Revenue This Year
- KLRS N/A
- MYO $55.29
- Revenue Next Year
- KLRS N/A
- MYO $27.18
- P/E Ratio
- KLRS N/A
- MYO N/A
- Revenue Growth
- KLRS N/A
- MYO 97.60
- 52 Week Low
- KLRS $2.38
- MYO $2.35
- 52 Week High
- KLRS $24.15
- MYO $7.17
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- MYO 20.55
- Support Level
- KLRS N/A
- MYO $2.70
- Resistance Level
- KLRS N/A
- MYO $2.89
- Average True Range (ATR)
- KLRS 0.00
- MYO 0.15
- MACD
- KLRS 0.00
- MYO 0.01
- Stochastic Oscillator
- KLRS 0.00
- MYO 12.93
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).